EndoCyclic Therapeutics announces FDA clearance

EndoCyclic Therapeutics has received Investigational New Drug (IND) application clearance from the FDA for ENDO-205. This first-in-class precision peptide therapeutic is designed for the non-hormonal treatment of endometriosis. The IND clearance allows the company to proceed with clinical trials, marking a critical milestone in the development of this novel therapy. EndoCyclic Therapeutics is focused on developing advanced peptide therapeutics and diagnostics for complex diseases, and this clearance advances their mission.